Zhongnan Medical Journal Press

Home Results

A total of 25 result was found. Results that relate to Economic

Cost-utility analysis of pembrolizumab combined with chemotherapy for advanced malignant pleural mesothelioma

Published on Chinese Journal of Pharmacoepidemiology 2024,33(10):1107-1114.
7923 times 1421 times

HU Yunjia ZOU Keqing HOU Yanhong

Pembrolizumab Chemotherapy Advanced malignant pleural mesothelioma Partitioned survival model Cost-utility analysis Pharmacoeconomic evaluation
Details
Economic evaluation of multi-station drug dispensing robots for intravenous infusion preparation

Published on Chinese Journal of Pharmacoepidemiology 2024,33(12):1375-1381.
14876 times 1103 times

SUN Zhihong ZHAO Shaoliang ZHOU Furong LIU Feiyu WANG Pengcheng ZOU Shaohua GUO Chenyu

Multi-station dispensing robot Pharmacy intravenous admixture services Dispensing efficiency Cost-effectiveness analysis Economic evaluation
Details
Pharmacoeconomic evaluation of third-line treatment of advanced non-small cell lung cancer with anlotinib

Published on Frontiers in Pharmaceutical Sciences 2024,28(4):639-647.
8614 times 969 times

YUAN Wenjie KANG Shuo WANG Xiaohui GONG Yuan PAN Zhenhua

Anlotinib Pharmacoeconomics Non-small cell lung cancer Cost-utility analysis
Details
Visualization analysis of research hotspots of the economic burden of acute ischemic stroke

Published on Chinese Journal of Pharmacoepidemiology 2025,34(1):78-85.
7016 times 988 times

BAI Yitong ZHAO Zhigang GUAN Zhongjun

Acute Ischemic Stroke Economic Burden Bibliometric Analysis Visualization analysis
Details
Cost-effectiveness analysis of low-dose steriod combined with tacrolimus or cyclophosphamide in the treatment of adult idiopathic membranous nephropathy

Published on Chinese Journal of Pharmacoepidemiology 2025,34(2):175-181.
7508 times 952 times

GUO Shanshan GUO Li LI Jiandong ZHENG Xijie CHEN Hang

Steroid Tacrolimus Idiopathic membranous nephropathy Decision tree model Pharmacoeconomics
Details
Analysis of the latent profiles and influencing factors of subjective economic toxicity in chronic patients

Published on New Medicine 2025,35(3):262-270.
3846 times 1034 times

ZHANG Zhen WEI Shiyi TIAN Yanzhen WU Yanxian CHEN Zhengying TIAN Liwen

Chronic diseases Economic toxicity Latent profile analysis Influencing factors
Details
Pharmacoeconomic evaluation of ribociclib plus fulvestrant in second-line treatment of HR+/HER2- advanced breast cancer for postmenopausal women

Published on Chinese Journal of Pharmacoepidemiology 2025,34(6):612-620.
6112 times 892 times

JIA Caifeng WANG Jie ZHANG Sen WANG Meiqi LI Sainan WANG Mingxia

Ribociclib Fulvestrant Advanced breast cancer Postmenopausal Pharmacoeconomic evaluation Cost-effectiveness analysis
Details
Sugemalimab as first-line treatment for non-small cell lung cancer: a rapid health technology assessment

Published on Chinese Journal of Pharmacoepidemiology 2025,34(7):806-814.
4656 times 662 times

HOU Yibing KANG Shuo GONG Yuan WANG Xiaohui NIE Ying LIU Huanlong

Sugemalimab Non-small cell lung cancer Effectiveness Safety Economics Rapid health technology assessment
Details
Cost-utility analysis of albumin paclitaxel combined with atezolizumab for the treatment of PD-L1-positive advanced triple-negative breast cancer

Published on Frontiers in Pharmaceutical Sciences 2025,29(7):1179-1185.
4963 times 565 times

HU Xiuping TAN Lunan LI Hongbo YAO Huitao

Albumin paclitaxel Atezolizumab Pharmacoeconomics Cost-utility analysis
Details
Sinicization and reliability and validity testing of the Chronic Disease Economic Toxicity Scale

Published on New Medicine 2025,35(8):940-946.
2054 times 621 times

ZHU Xiaoling WANG Lang TIAN Yanzhen ZHANG Zhen WEI Shiyi LI Qingfeng LONG Yanhong TANG Jie

Chronic disease Financial toxicity Chronic Disease Economic Toxicity Scale Transcultural adaptation Reliability Validity
Details